Shares in US retinal diseases specialist EyePoint Pharmaceuticals recovered from an early nosedive to close trading marginally higher on Wednesday. 6 February 2025
Kura Oncology and Japan’s Kyowa Kirin have announced that their menin inhibitor ziftomenib met the primary endpoint in a Phase II trial for relapsed or refractory acute myeloid leukemia (AML) 6 February 2025
US clinical-stage biotech Qlaris Bio has announced positive top-line results from two U.S. Phase II clinical trials investigating QLS-111 in patients with primary open angle glaucoma (POAG) and ocular hypertension (OHT). 6 February 2025
The New England Journal of Medicine has published results from the Phase II eNRGy trial for Bizengri (zenocutuzumab), a novel cancer med from Merus. 6 February 2025
Affinia Therapeutics, a US biotech with a pipeline of rationally designed adeno-associated virus (AAV) gene therapies for cardiovascular and neurological diseases, has announced the appointment of Hideo Makimura as its chief medical officer (CMO). 5 February 2025
In Düsseldorf, Algiax Pharmaceuticals is working on a novel analgesic which could provide an effective alternative to opioids, according to new mid-stage data. 5 February 2025
San Diego, USA-based Turnstone Biologics yesterday announced that it has completed an assessment of its business and operations, including the status of its program, resources, and capabilities. 5 February 2025
Spanish plasma-derived medicines specialist Grifols revealed it is collaborating with Dutch biotechnology start-up, FcR Therapeutics, to develop recombinant nanobodies to treat autoimmune diseases. 5 February 2025
AdvanCell announced the successful completion of an oversubscribed $112 million (US) Series C financing, making it the only Australian radiopharma company that has cash to burn. 4 February 2025
German biotech Akribion Therapeutics has emerged from stealth with 8 million euros ($9 million) in seed funding to accelerate the development of its novel RNA-guided precision medicines. 4 February 2025
Sionna Therapeutics hopes to raise $150 million and secure a market capitalization of about $692 million in an initial public offering (IPO). 4 February 2025
French drugmaker Mitem Pharma, which is dedicated to drugs of major therapeutic interest (DMTI), today revealed that has acquired the rights to Flisint (fumagillin) from pharma major Sanofi. 4 February 2025
California-based ImmunityBio has entered into a collaboration and supply agreement with Sino-American biotech BeiGene (to be changed to BeOne Medicines) combining the latter’s lead product Tevimbra (tislelizumab), a PD-1 checkpoint inhibitor (CPI), and ImmunityBio's Anktiva (nogapendekin alfa inbakicept-pmln). 3 February 2025
UK contract research organization hVIVO is gearing up to test an inhaled antiviral candidate, IN-002, for respiratory syncytial virus (RSV) in a Phase IIa human challenge trial. 3 February 2025
Blackstone, the world’s largest alternative asset manager, is expanding its presence in the life sciences sector with a new multibillion-dollar fund dedicated to drug development. 31 January 2025
Clinical-stage USA-based drug developer Inhibikase Therapeutics saw its shares tumble more than 31% to $1.92, after is revealed that it is pausing development of risvodetinib following disappointing results from a Phase II trial of patients with untreated Parkinson's disease. 31 January 2025
CNS-focused biopharma Axsome Therapeutics has won US Food and Drug Administration (FDA) approval for Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults. 31 January 2025
US clinical-stage biotech CARGO Therapeutics’ shares plummeted more than 75% to $3.23 yesterday, after it announced that it has elected to discontinue FIRCE-1, a Phase II clinical study of firicabtagene autoleucel (firi-cel). 31 January 2025
California-based immunology start-up Ouro Medicines, which is developing immune reset therapeutics for people living with chronic immune-mediated diseases, has announced its launch with $120 million in funding. 13 January 2025
UK pharma major GSK is to acquire IDRx, a Boston, USA-based, clinical-stage biopharma developing precision therapeutics for the treatment of gastrointestinal stromal tumors (GIST). 13 January 2025
Shares of USA-based Intra-Cellular Therapies leapt almost 36% to $128.85 in pre-marker activity today, as rumors of a takeover bid were confirmed. 13 January 2025
US biopharma Biohaven and Dutch biotech Merus have announced a research collaboration and license agreement to co-develop three novel bispecific antibody drug conjugates (ADCs). 13 January 2025
Artbio, a radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), has named Margaret Yu its chief medical officer (CMO). 10 January 2025
Chinese metabolic diseases specialist Hangzhou Sciwind Biosciences has announced details of a deal with Verdiva Bio for the global development and commercialization of a portfolio of therapies in territories outside of China and South Korea. 10 January 2025
USA-based Light Horse Therapeutics has been established as a new small molecule therapeutics developer, with a $62 million Series A financing led by founding investor Versant Ventures and partnered with Novartis to identify and develop potentially advanced therapeutics. 10 January 2025
Maryland, USA-based Veralox Therapeutics has picked up an option to acquire Nudge Therapeutics, along with its portfolio of preclinical cGAS inhibitor compounds. 10 January 2025
German biotech CatalYm has appointed Scott Clarke as chief executive (CEO), noting that he brings over two decades of executive leadership experience in driving company growth, developing products, and shaping and executing transactions in the biopharmaceutical industry. 10 January 2025
USA-based biotech builder Mountainfield Venture Partners and China’s Keymed Biosciences (HKEX: 02162) have joined forces to launch Timberlyne Therapeutics. 10 January 2025
European biotech start-ups Numab Therapeutics and AnaCardio have raised new funding to advance their pipelines, adding positive momentum to the sector at the start of the new year. 10 January 2025
USA-based Climb Bio said yesterday it has entered into an exclusive license agreement with Beijing Mabworks Biotech for rights to develop and commercialize MIL116 (now CLYM116), an anti-APRIL (A PRoliferation-Inducing Ligand) monoclonal antibody, in the territory outside of Greater China. 10 January 2025
Swiss oncology-focused Araris Biotech developing next-generation antibody drug conjugates (ADCs), today announced a research collaboration and option to license agreement (RCO) with Japan’s Chugai Pharmaceutical. 9 January 2025
UK headquartered Verdiva Bio Limited today announced its launch as a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and other cardiometabolic disorders. 9 January 2025
MaaT Pharma saw its shares rise by nearly 20% in early trading Thursday, following the announcement of positive topline results from a Phase III trial of its microbiome-based therapy, MaaT013. 9 January 2025
Canadian biotech Aspect Biosystems, which is developing bioprinted tissue therapeutics as a new category in regenerative medicine, has closed a $115 million Series B financing round. 8 January 2025
Insilico Medicine, a biotechnology firm specializing in artificial intelligence-powered drug discovery, has raised over $100 million in a series E funding round. 8 January 2025
Denmark’s Novo Nordisk and Valo Health today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (AI). 8 January 2025
Antag Therapeutics, a Denmark-based biopharma developing novel treatments for obesity, has announced the appointment of Joerg Moeller as chief executive officer, effective immediately. 8 January 2025
Privately-held US biotech Alloy Therapeutics has announced a target specific collaboration and license agreement for the use of its novel and proprietary anticlastic antisense platform with French pharma major Sanofi for a central nervous system (CNS) target. 8 January 2025